Is AOD-9604 actually effective for fat loss?
Probably not. Sumithran 2008 Phase 2b in 537 obese adults at four doses failed to differentiate from placebo over 24 weeks. The compound is still sold as a fat-loss peptide but the marketing predates the disappointing readout. Community reports exist but are inconsistent. For weight loss with real evidence, GLP-1s clear the bar by a wide margin.
Last reviewed · Panya.health editorial
What AOD-9604 actually is
AOD-9604 is a synthetic 16-amino-acid fragment (the C-terminal sequence of human growth hormone, residues 176-191) developed by Metabolic Pharmaceuticals in the 1990s and 2000s. The original mechanism hypothesis: this fragment retains HGH's lipolytic / fat-burning activity without the IGF-1-elevating, growth-promoting activity that limits HGH's safety. If true, this would be a clean fat-loss compound with none of HGH's downside profile. Animal studies in rodents were promising. Australian regulatory bodies granted limited approval for some indications based on the Phase 1 / 2 work.
What the actual Phase 2b trial showed
Sumithran et al. 2008 in Obesity ran 537 obese adults randomised to AOD-9604 doses (1 mg, 5 mg, 10 mg, 30 mg subcutaneous daily) or placebo over 24 weeks, with diet + exercise standardised across arms. Primary endpoint: body weight change at 24 weeks. The 1 mg dose showed a small statistically-significant reduction vs placebo, but the higher doses (5, 10, 30 mg) did not. The dose-response was inverted, which is biologically implausible for a real-effect compound and suggests the 1 mg result was likely chance. Metabolic Pharmaceuticals discontinued obesity development after this readout. The compound has been recycled into joint-pain protocols (Phase 2 in osteoarthritis) without clean efficacy results.
Why it's still sold and what users actually report
The marketing infrastructure for AOD-9604 as a fat-loss peptide predates the 2008 negative readout and never fully retracted. Wellness clinics, telehealth services, and research-chem vendors continue to sell it for fat-loss claims. Community subjective reports vary widely: some users report meaningful fat-loss alongside diet + exercise (which makes attribution hard given diet + exercise alone produces fat loss), others report no effect at any dose. The weight of the evidence sits closer to placebo than to a real fat-loss compound. For users specifically wanting fat-loss-only without the muscle-building or appetite-suppression profile of other compounds, the honest answer is that this is the wrong tool. GLP-1s for appetite-mediated weight loss, tesofensine for stimulant-class central appetite suppression, retatrutide for the future Phase 3 readout: all three clear the evidence bar by a wide margin.
Where Panya stands
AOD-9604 is documented at panya.health/peptide/aod-9604 with the negative Phase 2b trial result called out explicitly. Panya does NOT yet route to vendors for AOD-9604 because (a) the evidence case is weak, (b) non-GLP-1 vendor scoring is gated on lawyer review. The compound is widely sold in research-chem space and at some Bangkok wellness clinics; the Panya documentation page is positioned to surface the trial reality that vendor marketing tends to omit.
Read about this peptide
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.